Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal, Respiratory and Neurological Conditions Due to Impaired Taste and Smell.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Covid-19 Recurrent
- Sponsor
- Clinica Gema Leon
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- ad hoc patient survey
- Status
- Not Yet Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is:
- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.
Researchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off).
Participants will:
- Be evaluated before starting treatment.
- Be evaluated 3 weeks after.
- Be evaluated at 5 weeks, or 15 sessions or completion of treatment.
- Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
Detailed Description
The waves of Sars-Cov-2 disease continue to be continuous and we are increasingly aware of the consequences it causes both in the respiratory system, musculoskeletal system and in the central and peripheral nervous system. Likewise, non-invasive neuromodulation acts with a pump of ions, generating endogenous stimuli that modulate the central nervous system. The aim of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. To carry out this study, pain was measured with the visual analogue scale. It was also measured the joint amplitude, a muscle assessment with the help of a strength dynamometer, the patient's independence with the Katz index and the functionality of the lower or upper limbs, depending on the affected joint.
Investigators
GEMA LEÓN BRAVO
Principal Investigator
Clinica Gema Leon
Eligibility Criteria
Inclusion Criteria
- •Patients between the ages of 18 and
- •Patients with a positive diagnosis of COVID-
- •Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases.
- •Patients who signed the informed consent.
- •Exclusion criteria:
- •Patients aged before 18 years and after 60 years.
- •Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases
- •Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
ad hoc patient survey
Time Frame: one month
survey of patients about conditions diagnosed during the illness and those they suffer from after infection that are directly related to abnormalities to be assessed.
sex, age, vaccination and number of months with symptoms
Time Frame: one month
Nominal variables such as sex, age, vaccination and number of months with symptoms
Number of participants with musculoskeletal, respiratory and neurological sequelae of taste and smell after COVID-19
Time Frame: three months
Secondary Outcomes
- SDOQ-NS questionnaire for social impairments due to loss of smell(two months)
- SF12 Quality of Life Questionnaire(two months)
- Brief Smell Identification Test: Assessment of smell.(two months)
- EuroQoL 5-D scale (validated translation into Spanish) for quality of life.(two months)
- upper limb functional index(two months)
- lower limb functional index(two months)
- Visual analogue scale (VAS), for pain assessment(two months)
- Sensory assessment for pain and light touch(two months)
- Sadoul's dyspnea rating scale.(two months)
- measurement of lung function with spirometry and lung volume testing(three months)